Literature DB >> 6822741

Studies of a high molecular weight human melanoma-associated antigen.

I Hellström, H J Garrigues, L Cabasco, G H Mosely, J P Brown, K E Hellström.   

Abstract

Hybridomas were generated by fusing SP2/0 mouse myeloma cells with spleen cells from mice that had been immunized with cultured human melanoma cells. One of the hybridomas secreted a monoclonal IgG1 antibody, 48.7, which binds to a cell surface antigen of cells from human melanomas and compound nevi. The presence of the target antigen in vivo was demonstrated immunohistologically by staining frozen sections of primary and metastatic melanoma by the peroxidase anti-peroxidase technique. Weak staining of some blood vessel cells was also seen, but other normal cells, including skin melanocytes, were unstained, as were cells from other tumor types. Antibody 48.7 immunoprecipitated polypeptides with apparent m.w. on sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 250,000 and greater than 400,000.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822741

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

2.  Radioimmunoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: a comparison of the clinical and immunohistochemical results.

Authors:  D F Schaling; J P van der Pol; M J Jager; M J van Kroonenburgh; J A Oosterhuis; D J Ruiter
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

3.  Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement.

Authors:  B Wang; Y B Chen; O Ayalon; J Bender; A Garen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

4.  Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumours. An immunohistochemical study on paraffin sections.

Authors:  R Colombari; F Bonetti; G Zamboni; A Scarpa; F Marino; A Tomezzoli; P Capelli; F Menestrina; M Chilosi; L Fiore-Donati
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

5.  Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.

Authors:  I Hellström; V Brankovan; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

6.  Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.

Authors:  P Shamamian; M Mancini; Y Kawakami; N P Restifo; S A Rosenberg; S L Topalian
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

Review 7.  Diagnostic and therapeutic use of monoclonal antibodies to human tumor antigens.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

8.  Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection.

Authors:  M T Lotze; J A Carrasquillo; J N Weinstein; G J Bryant; P Perentesis; J C Reynolds; L A Matis; R R Eger; A M Keenan; I Hellström
Journal:  Ann Surg       Date:  1986-09       Impact factor: 12.969

9.  In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.

Authors:  B Holzmann; J P Johnson; P Kaudewitz; G Riethmüller
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

10.  The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface.

Authors:  H J Garrigues; M W Lark; S Lara; I Hellström; K E Hellström; T N Wight
Journal:  J Cell Biol       Date:  1986-11       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.